Gilead Sciences Inc. (GILD) Given “Outperform” Rating at Leerink Swann
Leerink Swann reaffirmed their outperform rating on shares of Gilead Sciences Inc. (NASDAQ:GILD) in a research note published on Friday morning. Leerink Swann currently has a $112.00 price target on the biopharmaceutical company’s stock.
GILD has been the subject of several other research reports. Jefferies Group cut their price objective on Gilead Sciences from $93.00 to $91.00 and set a hold rating for the company in a report on Wednesday, August 31st. Zacks Investment Research raised Gilead Sciences from a sell rating to a hold rating in a report on Monday, September 26th. Piper Jaffray Cos. reissued an overweight rating and set a $108.00 price objective on shares of Gilead Sciences in a report on Wednesday, August 31st. Vetr raised Gilead Sciences from a buy rating to a strong-buy rating and set a $93.97 target price for the company in a research note on Tuesday, July 26th. Finally, S&P Equity Research reaffirmed a strong-buy rating on shares of Gilead Sciences in a research note on Wednesday, July 27th. Ten investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $105.00.
Shares of Gilead Sciences (NASDAQ:GILD) traded down 2.1016% during mid-day trading on Friday, hitting $77.4572. 2,164,980 shares of the stock traded hands. The firm’s 50-day moving average is $79.40 and its 200-day moving average is $85.53. Gilead Sciences has a 52 week low of $76.67 and a 52 week high of $111.11. The stock has a market cap of $102.22 billion, a price-to-earnings ratio of 6.7981 and a beta of 1.10.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.02 by $0.06. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The company earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. During the same quarter in the previous year, the firm earned $3.15 earnings per share. Gilead Sciences’s revenue was down 5.7% on a year-over-year basis. On average, analysts forecast that Gilead Sciences will post $11.76 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were paid a $0.47 dividend. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.38%. Gilead Sciences’s payout ratio is 16.56%.
In other Gilead Sciences news, CEO John F. Milligan sold 112,000 shares of the stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $84.33, for a total transaction of $9,444,960.00. Following the completion of the transaction, the chief executive officer now owns 1,170,963 shares of the company’s stock, valued at $98,747,309.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $81.84, for a total value of $409,200.00. Following the transaction, the executive vice president now directly owns 132,964 shares of the company’s stock, valued at approximately $10,881,773.76. The disclosure for this sale can be found here. 1.40% of the stock is owned by insiders.
Several institutional investors have recently made changes to their positions in GILD. Bank of Montreal Can bought a new stake in Gilead Sciences during the second quarter valued at approximately $427,750,000. Capital World Investors boosted its stake in Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock valued at $1,277,907,000 after buying an additional 3,380,000 shares in the last quarter. Investec Asset Management LTD bought a new stake in Gilead Sciences during the first quarter valued at approximately $280,342,000. Parnassus Investments CA boosted its stake in Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock valued at $705,774,000 after buying an additional 2,640,284 shares in the last quarter. Finally, NN Investment Partners Holdings N.V. bought a new stake in Gilead Sciences during the first quarter valued at approximately $180,268,000. 77.94% of the stock is owned by institutional investors and hedge funds.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.